Drugs / MSC11FCD
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07143812 | Oct 2025 → Dec 2026 expected | glioblastoma | CHA University | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04657315 | Jun 2020 → Dec 2022 | gliosarcoma | CHA University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSC11FCD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04657315 ↗ |
| Modality | Cell therapy | “Mesenchymal stem cells into which the suicide gene, cytosine deaminase (CD)” NCT04657315 ↗ |
| Route | Other | “Route of administration: Intratumoral administration” NCT04657315 ↗ |